AI
FULC icon

Atom Investors’s Fulcrum Therapeutics FULC Stock Holding History

Atom Investors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$530K Buy
69,155
+8,560
+14% +$79.4K 0.04% 468
2025
Q4 		$685K Buy
+60,595
New +$617K 0.05% 352
2024
Q2 		– Sell
-12,658
Closed -$119K – 549
2024
Q1 		$119K Buy
+12,658
New +$113K 0.01% 511

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Atom Investors's FULC Position: Q1 2026 in Review

Atom Investors increased its Fulcrum Therapeutics (FULC) stake by 14% in Q1 2026, buying an estimated $79.4K and bringing the position to 69,155 shares worth $530K. The position accounts for 0.04% of the portfolio, ranked #468.

Atom Investors first reported a position in FULC in Q1 2024 and has held it in 3 quarters since. The position peaked at $685K in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Atom Investors held 69,155 shares of Fulcrum Therapeutics worth $530K as of Q1 2026.
  • Atom Investors bought 8,560 Fulcrum Therapeutics shares in Q1 2026, an estimated $79.4K.
  • Fulcrum Therapeutics made up 0.04% of Atom Investors's portfolio in Q1 2026, its #468 holding.
  • Atom Investors first reported a position in Fulcrum Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Atom Investors's Fulcrum Therapeutics position peaked at $685K in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Atom Investors's 13F filing for Q1 2026, filed 15 May 2026.